This review (2017) presents the findings from all six modern clinical studies using LSD in the previous 25 years, detailing the effects and suggested mechanism of action in both healthy participants and those with end-of-life anxiety.
Abstract of Modern clinical research on LSD
“All modern clinical studies using the classic hallucinogen lysergic acid diethylamide (LSD) in healthy subjects or patients in the last 25 years are reviewed herein. There were five recent studies in healthy participants and one in patients. In a controlled setting, LSD acutely induced bliss, audiovisual synesthesia, altered meaning of perceptions, derealization, depersonalization, and mystical experiences. These subjective effects of LSD were mediated by the 5-HT2A receptor. LSD increased feelings of closeness to others, openness, trust, and suggestibility. LSD impaired the recognition of sad and fearful faces, reduced left amygdala reactivity to fearful faces, and enhanced emotional empathy. LSD increased the emotional response to music and the meaning of music. LSD acutely produced deficits in sensorimotor gating, similar to observations in schizophrenia. LSD had weak autonomic stimulant effects and elevated plasma cortisol, prolactin, and oxytocin levels. Resting-state functional magnetic resonance studies showed that LSD acutely reduced the integrity of functional brain networks and increased connectivity between networks that normally are more dissociated. LSD increased functional thalamocortical connectivity and functional connectivity of the primary visual cortex with other brain areas. The latter effect was correlated with subjective hallucinations. LSD acutely induced global increases in brain entropy that were associated with greater trait openness 14 days later. In patients with anxiety associated with life-threatening disease, anxiety was reduced for 2 months after two doses of LSD. In medical settings, no complications of LSD administration were observed. These data should contribute to further investigations of the therapeutic potential of LSD in psychiatry.”
Author: Matthias E. Liechti
Summary of Modern clinical research on LSD
This article from 20217 reviews recent controlled clinical studies of lysergic acid diethylamide (LSD) in psychiatry research. It does not cover older studies published before the prohibition of LSD.
History
LSD was first synthesized in 1938, and its psychoactive properties were discovered in 1943. It was used to model psychosis and investigate anxiety associated with terminal cancer, alcoholism, opioid use disorder, and depression. Clinical research on LSD stopped in the early 1970s but has since gained momentum. The first modern research findings on LSD, psilocybin, and ayahuasca in psychiatric patients have only recently been published.
Find this paper
Modern clinical research on LSD
https://doi.org/10.1038/npp.2017.86
Open Access | Google Scholar | Backup | 🕊
Cite this paper (APA)
Liechti, M. E. (2017). Modern clinical research on LSD. Neuropsychopharmacology, 42(11), 2114-2127.
Authors
Authors associated with this publication with profiles on Blossom
Matthias LiechtiMatthias Emanuel Liechti is the research group leader at the Liechti Lab at the University of Basel.